At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Biospecimen Collection, Bone Marrow Aspiration, and 6 other interventions for Acute Myeloid Leukemia. Active but no longer recruiting, targeting 267 participants across 188 sites.
Detailed Summary
This phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with uproleselan may work better in treating patients with acute myeloid leukemia compared to daunorubicin and cytarabine alone.
Study Details
Timeline
Interventions
Undergo blood collection
Undergo bone marrow aspirate
Undergo bone marrow biopsy
Given IV
Given IV
Undergo ECHO
Undergo MUGA
Given IV